Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Rosiglitazone" patented technology

Rosiglitazone is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.

Novel co-crystal of saroglitazar with poly(d-glucosamine)

The present invention relates to novel Poly(D-glucosamine) co-crystals of Saroglitazar. Specifically, the present invention provides co-crystal of Saroglitazar of formula (I) and Chitosan, process for the preparation of said co-crystal, use thereof and pharmaceutical compositions comprising the same.
Owner:ZYDUS LIFESCIENCES LTD

Culture medium for improving synthesis of unsaturated fatty acid in cell culture fat

PendingCN121991887ASkeletal/connective tissue cellsIndometacinMethyl xanthine
The invention relates to the technical field of biological culture, and particularly discloses a culture medium for improving synthesis of unsaturated fatty acid in cell culture fat, which is used for solving the problem that the content of unsaturated fatty acid in the culture fat is not satisfactory. The differentiation culture medium comprises the following components: a basic culture medium, a specific porcine adipose-derived mesenchymal stem cell differentiation induction factor and an unsaturated fatty acid additive. Wherein the specific induction factors comprise but are not limited to factors such as insulin, dexamethasone, indometacin, 3-isobutyl-1-methylxanthine, rosiglitazone and the like. The unsaturated fatty acid additive comprises alpha-linolenic acid, and by adding the substances into the culture medium, the differentiation efficiency of the porcine adipose-derived mesenchymal stem cells and the directional synthesis of the unsaturated fatty acid in the cells can be improved. According to the improved differential culture medium, cell differentiation and unsaturated fatty acid synthesis are effectively promoted by optimizing components and proportions, and the improved differential culture medium has an important application prospect.
Owner:XINXIANG MEDICAL UNIV

Induced differentiation method of sebaceous gland cells

The invention discloses an induced differentiation method of sebaceous gland cells, which comprises the following specific steps: adding epidermal stem cells into an induction culture medium, and carrying out induced culture for 5-7 days to obtain the sebaceous gland cells, wherein the adopted induction culture medium is not added with insulin and specifically comprises the following components: 50% of a keratinocyte culture medium, 50% of a sebaceous gland cell culture medium, 1% of antibiotics, 20-40 ng / mL of EGF, 10-40 ng / mL of KGF and 5-20 ng / mL of rosiglitazone. Growth factors EGF and KGF and rosiglitazone are simultaneously added into the induction culture medium, insulin is completely not added, normal division and proliferation of cells are guaranteed, and sebaceous gland cells which are good in growth state and high in differentiation degree are obtained in a short culture period; compared with SZ95, the expression quantities of various sebaceous gland cell markers are similar.
Owner:SHANGHAI JAKA BIOTECH CO LTD +1

A dual-unit fluorescent sensor array for detecting oral anti-diabetic drugs and use thereof

PendingCN122361371ADiabrezideHypoglycemia
The application discloses a dual-unit fluorescent sensor array for detecting oral anti-diabetic drugs and application thereof, and relates to a supramolecular fluorescent sensor array which comprises a PAL@Q[8] sensing unit and a bpep-Am@Q[8] sensing unit, wherein the PAL@Q[8] sensing unit is composed of palmatine and Q[8], and the bpep-Am@Q[8] sensing unit is composed of a derivative of 1,4-bis[2-(4-pyridyl)vinyl]benzene and Q[8]. The dual-unit fluorescent sensor array can be used for qualitative detection and quantitative detection of metformin, phenformin, buformin hydrochloride, rosiglitazone and sitagliptin in serum or urine, and the method provides a simple and reliable analysis tool for rapid screening of oral hypoglycemic drugs, clinical blood drug concentration monitoring and identification of hypoglycemia causes, so as to realize on-site rapid visual analysis of oral hypoglycemic drugs.
Owner:GUIZHOU UNIV